Physician profile
Mark H Lowitt
NPI 1326015611
$423.55
in general payments reported to CMS, 2019-2025
12 companies · $409 in 2025
The $409 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $15.00 · 2025: $409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $409.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $408.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $84.81 | 2025 | |
| Galderma Laboratories, L.P. | $56.24 | 2025 | Nemluvio, Aklief |
| Pfizer INC. | $51.01 | 2022-2025 | |
| Incyte Corporation | $44.25 | 2025 | Opzelura |
| Abbvie INC. | $29.38 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.09 | 2025 | Spevigo |
| Regeneron Healthcare Solutions, INC. | $24.72 | 2025 | Dupixent |
| Journey Medical Corporation | $23.97 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $23.40 | 2025 | Sotyktu |
| Amgen INC. | $21.33 | 2025 | Otezla |
| Sun Pharmaceutical Industries INC. | $20.54 | 2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $16.81 | 2025 | Cabtreo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Lowitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.